HomeDMYD-B • STO
add
Diamyd Medical AB
Previous close
kr 10.52
Day range
kr 10.30 - kr 10.60
Year range
kr 7.50 - kr 19.50
Market cap
1.40B SEK
Avg Volume
337.32K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Aug 2025info | Y/Y change |
|---|---|---|
Revenue | 18.00K | -5.26% |
Operating expense | 45.81M | -10.43% |
Net income | -44.86M | 9.80% |
Net profit margin | -249.24K | 4.79% |
Earnings per share | — | — |
EBITDA | -44.87M | 11.12% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Aug 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 277.18M | 109.41% |
Total assets | 352.64M | 62.48% |
Total liabilities | 72.64M | 2.14% |
Total equity | 280.00M | — |
Shares outstanding | 137.50M | — |
Price to book | 5.16 | — |
Return on assets | -30.90% | — |
Return on capital | -38.46% | — |
Cash Flow
Net change in cash
| (SEK) | Aug 2025info | Y/Y change |
|---|---|---|
Net income | -44.86M | 9.80% |
Cash from operations | -35.94M | -23.25% |
Cash from investing | -2.18M | -111.62% |
Cash from financing | -1.07M | -28.16% |
Net change in cash | -42.08M | -309.55% |
Free cash flow | -26.08M | -42.66% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
33
